{
  "kind": "treatment",
  "slug": "divalproex-sodium-depakote",
  "type": "mood-stabilizer",
  "name": "Divalproex Sodium (Depakote)",
  "summary": "An anticonvulsant and mood stabilizer used for bipolar disorder, epilepsy, and migraine prophylaxis.",
  "description": "Divalproex sodium is a compound of sodium valproate and valproic acid in a 1:1 ratio, designed to improve gastrointestinal tolerability. It is widely used in psychiatry as a mood stabilizer for acute mania, mixed episodes, and maintenance in bipolar disorder. Additionally, it is prescribed for seizure disorders and migraine prophylaxis.",
  "category": "medications/mood-stabilizers",
  "tags": [
    "bipolar-disorder",
    "mania",
    "mood-stabilizer",
    "anticonvulsant"
  ],
  "metadata": {
    "drug_classes": [
      "Anticonvulsant",
      "Mood Stabilizer"
    ],
    "therapeutic_categories": [
      "Bipolar Disorder",
      "Epilepsy",
      "Migraine Prevention"
    ],
    "mechanism_categories": [
      "GABA",
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Depakote",
      "Depakote ER"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "D (X for migraine prevention in pregnancy)",
    "age_groups": [
      "Adult",
      "Adolescent"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Neurology"
    ],
    "fda_approval_year": 1983
  },
  "clinical_metadata": {
    "primary_indications": [
      "Bipolar",
      "Seizures",
      "Other"
    ],
    "off_label_uses": [
      "Agitation in dementia",
      "Impulse control disorders",
      "Schizoaffective disorder"
    ],
    "contraindications": [
      "Hepatic disease or significant hepatic dysfunction",
      "Urea cycle disorders",
      "Mitochondrial disorders caused by POLG mutations"
    ],
    "monitoring_required": [
      "Liver function tests",
      "CBC with platelets",
      "Valproate serum levels",
      "Ammonia levels if symptomatic"
    ],
    "efficacy_rating": {
      "mania": 4,
      "bipolar-maintenance": 3,
      "seizures": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "divalproex sodium",
      "depakote",
      "valproate",
      "mood stabilizer"
    ],
    "synonyms": [
      "sodium valproate + valproic acid",
      "valproate compound"
    ],
    "common_misspellings": [
      "divalproax",
      "depakot"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Acute treatment of manic or mixed episodes in bipolar disorder",
        "Maintenance treatment in bipolar disorder",
        "Epilepsy (various seizure types)",
        "Migraine prophylaxis"
      ]
    },
    {
      "type": "mechanism",
      "text": "Increases brain concentrations of gamma-aminobutyric acid (GABA) by inhibiting GABA transaminase, modulates voltage-gated sodium channels, and influences T-type calcium channels, stabilizing neuronal firing."
    },
    {
      "type": "dosing",
      "adult": {
        "mania": "Initial 750 mg/day in divided doses; titrate rapidly to clinical effect; therapeutic serum level: 50–125 mcg/mL",
        "maintenance": "Adjust to maintain serum levels within target range",
        "migraine": "250 mg twice daily, may increase to 1000 mg/day",
        "epilepsy": "10–15 mg/kg/day, increase by 5–10 mg/kg/week; max 60 mg/kg/day"
      },
      "geriatric": "Start at lower dose, monitor closely for sedation and hepatic function",
      "hepatic_impairment": "Contraindicated in severe hepatic impairment",
      "renal_impairment": "No adjustment needed, but monitor protein binding and free valproate"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets (delayed-release): 125 mg, 250 mg, 500 mg",
        "Tablets (extended-release): 250 mg, 500 mg",
        "Sprinkle capsules: 125 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset for mania control is usually within a few days; steady state is reached in 2–4 days; half-life ranges 9–16 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "nausea",
        "vomiting",
        "tremor",
        "weight gain",
        "hair loss",
        "sedation"
      ],
      "less_common": [
        "ataxia",
        "diplopia",
        "thrombocytopenia",
        "edema"
      ],
      "serious": [
        "hepatotoxicity",
        "pancreatitis",
        "hyperammonemic encephalopathy",
        "teratogenicity (neural tube defects)"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Hepatotoxicity, pancreatitis, teratogenicity; contraindicated in pregnancy for migraine prophylaxis.",
      "other": [
        "May cause dose-related thrombocytopenia",
        "Caution in patients with mitochondrial disorders",
        "Avoid abrupt discontinuation to prevent seizure risk"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Lamotrigine",
          "risk": "Increased lamotrigine levels and risk of rash",
          "action": "Reduce lamotrigine dose by 50%"
        },
        {
          "with": "Aspirin",
          "risk": "Increased free valproate levels",
          "action": "Monitor levels"
        },
        {
          "with": "Carbapenem antibiotics",
          "risk": "Reduced valproate levels",
          "action": "Avoid combination"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Serum valproate concentration",
        "Liver function tests at baseline and regularly",
        "CBC with platelets",
        "Ammonia levels if altered mental status"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Contraindicated for migraine prophylaxis; high teratogenic risk; avoid unless no alternatives",
      "lactation": "Excreted in breast milk; weigh benefits and risks",
      "pediatrics": "Approved for seizure disorders; caution for hepatotoxicity in children under 2",
      "geriatrics": "More sensitive to sedation and tremor; monitor closely"
    },
    {
      "type": "tapering",
      "text": "Taper gradually over weeks to prevent relapse or seizure recurrence."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Extended-release formulation allows once-daily dosing",
        "Monitor weight and metabolic parameters during long-term use",
        "Educate patients about early symptoms of liver or pancreas problems"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Depakote Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "CANMAT Bipolar Guidelines",
          "url": "https://www.canmat.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Divalproex Sodium (Depakote): Mood Stabilizer for Bipolar Disorder and Epilepsy",
    "description": "Divalproex sodium (Depakote) is a mood stabilizer and anticonvulsant used for bipolar disorder, epilepsy, and migraine prophylaxis."
  }
}
